1-8 of 8
Martin Mueller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Hartmut Goldschmidt, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Michael Hundemer, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc-Steffen Raab, Martin Hoffmann, Katja C. Weisel, Hans Salwender, Elias K. Mai
Journal: Blood
Blood (2024) 144 (Supplement 1): 769.
https://doi.org/10.1182/blood-2024-193308
Published: 2024
Journal Articles

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Elias K. Mai, Hans Salwender, Michael Hundemer, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Niels Weinhold, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc S. Raab, Martin Hoffmann, Katja C. Weisel, Hartmut Goldschmidt
Journal: Blood
Blood (2024) 144 (Supplement 1): 364.
https://doi.org/10.1182/blood-2024-194768
Published: 2024
Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Hartmut Goldschmidt, Elias K Mai, Eva Nievergall, Roland Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana v. Metzler, Mathias Haenel, Christoph Mann, Anne-Marie Asemissen, Bernhard Heilmeier, Stefanie Huhn, Katharina Kriegsmann, Niels Weinhold, Steffen P. Luntz, Tobias A. W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Cyrus Khandanpour, Wolfgang Knauf, Markus Munder, Thomas Geer, Hendrik Riesenberg, Joerg Thomalla, Martin Hoffmann, Marc-Steffen Raab, Hans Salwender, Katja Weisel
Journal: Blood
Blood (2021) 138 (Supplement 1): 463.
https://doi.org/10.1182/blood-2021-145097
Published: 2021
Journal Articles

High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.

Paolo G Vigneri, Fabio Stagno, Stefania Stella, Alessandra Cupri, Stefano Forte, Michele Massimino, Agostino Antolino, MD, Clementina Caracciolo, Laura Nocilli, Stefana Impera, Caterina Musolino, MD, Diamante Turri, Mario Russo, Carmen Tomaselli, Michele Rizzo, Maurizio Musso, Fortunato Morabito, Luciano Levato, Livia Manzella, Martin Mueller, MD, Francesco Di Raimondo, MD
Journal: Blood
Blood (2012) 120 (21): 2790.
https://doi.org/10.1182/blood.V120.21.2790.2790
Published: 2012
Journal Articles

Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.

Susan Branford, Andreas Hochhaus, Martin Mueller, Erkut Bahceci, Lynn Ploughman, Jaydip Mukhopadhyay, Timothy Hughes
Journal: Blood
Blood (2009) 114 (22): 3282.
https://doi.org/10.1182/blood.V114.22.3282.3282
Published: 2009
Journal Articles

Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.

Timothy Hughes, Giuseppe Saglio, Giovanni Martinelli, Dong-Wook Kim, S. Soverini, Martin Mueller, A. Haque, N. Gallagher, Y. Shou, Jerald Radich, Susan Branford, Andreas Hochhaus
Journal: Blood
Blood (2007) 110 (11): 320.
https://doi.org/10.1182/blood.V110.11.320.320
Published: 2007
Journal Articles

In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.

Guntram Buesche, Rudiger Hehlmann, Arnold Ganser, Hartmut Hecker, Andreas Hochhaus, Hermann Heimpel, Barbara Heinze, Claudia Schoch, PD., Dorothea Gadzicki, Martin Mueller, Nils von Neuhoff, Susanne Schnittger, PD., Brigitte Schlegelberger, Bernd Frye, Axel Georgii, Hans Kreipe
Journal: Blood
Blood (2006) 108 (11): 2195.
https://doi.org/10.1182/blood.V108.11.2195.2195
Published: 2006
Journal Articles

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Heike Pfeifer, MD, Barbara Wassmann, MD, Anni Pavlova, MD, Martin Mueller, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Johannes Oldenburg, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD
Journal: Blood
Blood (2005) 106 (11): 147.
https://doi.org/10.1182/blood.V106.11.147.147
Published: 2005